

Major Products

Japan Business Unit

Brand Name (Generic Name)	Efficacy	Launched	Remarks	Revenue (Billions of yen)	
				FY2021 results	YoY
				489.5	0.4
<i>Emgality</i> (<i>galcanezumab</i>)	Prophylaxis of migraine attacks	2021	Humanized CGRP monoclonal antibody. It binds specifically to calcitonin gene-related peptide (CGRP), which is considered to be associated with migraine, and thereby inhibits migraine attacks.	4.6	4.6
<i>Enhertu</i> (<i>trastuzumab deruxtecan</i>)	Anti-cancer agent (HER2 directed antibody drug conjugate)	2020	Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.	9.6	5.2
<i>Tarlige</i> (<i>mirogabalin</i>)	Pain treatment	2019	An $\alpha 2 \delta$ ligand. The pain therapy agent to reduce the neurotransmitter release from nerve terminals.	30.1	9.6
<i>Canalia</i> (<i>teneligliptin / canagliflozin</i>)	Type 2 diabetes mellitus treatment	2017	A first combination drug of the DPP-4 inhibitor teneligliptin and the SGLT2 inhibitor <i>canagliflozin</i> approved in Japan, which demonstrates blood glucose-lowering activity through a complementary pharmacological effect.	16.8	1.4
<i>Vimpat</i> (<i>lacosamide</i>)	Anti-epileptic agent	2016	Sodium channel blocker. Suppresses the excessive excitation of nerves in the brain, and reduces the occurrence of epileptic seizures.	18.3	3.7
<i>Efient</i> (<i>prasugrel</i>)	Antiplatelet agent	2014	ADP receptor inhibitor. Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion due to thrombosis.	16.7	2.7
<i>Pralia</i> (<i>denosumab</i>)	Treatment for osteoporosis / inhibitor for rheumatoid arthritis-induced progression of bone erosion	2013	Human monoclonal anti-RANKL antibody. Subcutaneous formulation which controls bone resorption and bone destruction by specifically inhibiting RANKL.	37.9	3.3
<i>Tenelia</i> (<i>teneligliptin</i>)	Type 2 diabetes mellitus treatment	2012	DPP-4 inhibitor. The agent facilitates glucose-dependent insulin release and inhibits glucagon release, thereby demonstrating the blood glucose-lowering activity.	23.7	-0.6
<i>Ranmark</i> (<i>denosumab</i>)	Treatment for bone disorders caused by bone metastases from tumors	2012	Human monoclonal anti-RANKL antibody. This controls abnormal bone destruction caused by osteoclasts, and reduces the occurrence of fractures and other skeletal related events (SRE). Approved for the indication of giant cell tumors of bone in 2014 and was designated as an orphan drug.	20.4	1.1
<i>Lixiana</i> (<i>edoxaban</i>)	Anticoagulant	2011	Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.	92.5	15.1
<i>Inavir</i> (<i>laninamivir</i>)	Anti-influenza treatment	2010	Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.	1.3	-2.3
<i>Rezaltas</i> (<i>olmesartan</i>)	Antihypertensive agent	2010	A combination drug of two antihypertensive agents: an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> , and a calcium ion antagonist, <i>azelnidipine</i> . This combination demonstrates the effect of decreasing blood pressure through a complementary pharmacological effect.	12.0	-1.1
<i>Loxonin</i> (<i>loxoprofen</i>)	Anti-inflammatory analgesic	1986	Nonsteroidal anti-inflammatory analgesic. Suppresses the production of prostaglandin associated with inflammation, and thereby demonstrates an analgesic effect. Also available as transdermal agents (poultice, gel, tape).	22.2	-2.0
(Daiichi Sankyo Espha products)				82.8	11.4
(Vaccines business)				14.8	-3.7

Japan Business Unit (Daiichi Sankyo Espha products)

Brand Name	Efficacy
<i>Olmesartan</i>	Antihypertensive agent
<i>Memantine OD</i>	Alzheimer's disease treatment
<i>Gefitinib</i>	Treatment for malignant tumors
<i>Bicalutamide</i>	Prostate cancer treatment
<i>Tamoxifen</i>	Anti-breast cancer agent

Japan Business Unit (Vaccines business)

Brand Name
<i>Influenza HA Vaccine</i>
<i>Live Attenuated Measles-Rubella Combined Vaccine</i>
<i>Live Attenuated Mumps Vaccine</i>
<i>H5N1 Influenza Vaccines</i>



Enhertu



Lixiana

Oncology Business Unit

Brand Name (Generic Name)	Efficacy	Launched	Remarks	Revenue (Billions of yen)	
				FY2021 results	YoY
				69.6	22.2
<i>Enhertu</i> (<i>trastuzumab deruxtecan</i>)	Anti-cancer agent (HER2 directed antibody drug conjugate)	2020	Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.	54.4	28.7
<i>TURALIO</i> (<i>pexidartinib</i>)	Treatment for symptomatic tenosynovial giant cell tumor (TGCT)	2019	<i>TURALIO</i> is an oral small molecule that inhibits CSF1R (colony stimulating factor-1 receptor), which is a primary growth driver of abnormal cells in the synovium that cause TGCT.	2.8	1.0

American Regent Unit

Brand Name (Generic Name)	Efficacy	Launched	Remarks	Revenue (Billions of yen)	
				FY2021 results	YoY
				149.5	27.7
<i>Injectafer</i> (<i>ferric carboxymaltose injection</i>)	Iron deficiency anemia treatment	2013	Effective for patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis-dependent chronic kidney disease	53.1	8.9
<i>Venofer</i> (<i>iron sucrose injection</i>)	Iron deficiency anemia treatment	2000	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients, etc.	33.8	4.9

EU Specialty Business Unit

Brand Name (Generic Name)	Efficacy	Launched	Remarks	Revenue (Billions of yen)	
				FY2021 results	YoY
				128.2	16.6
<i>Nilemdo / Nustendi</i> (<i>bempedoic acid or combination tablet of bempedoic acid and ezetimibe</i>)	Cholesterol-lowering treatment	2020	Bempedoic acid is an oral treatment which lowers cholesterol. It inhibits ATP Citrate Lyase, an enzyme which is involved in the production of cholesterol in the liver. Bempedoic acid/ezetimibe reduces absorption of dietary cholesterol in the gut; it is an oral treatment which combines two complementary ways of reducing blood cholesterol levels.	3.1	2.6
<i>Lixiana</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.	96.9	20.2
<i>Olmetec</i>	Antihypertensive agent	2002	<i>Olmetec: Olmesartan</i>	20.3	-1.2
<i>Olmetec Plus</i>		2005	<i>Olmetec Plus: A combination drug of olmesartan medoxomil and hydrochlorothiazide (diuretic)</i>		
<i>Sevikar</i> (<i>olmesartan</i>)		2009	<i>Sevikar: A combination drug of olmesartan medoxomil and amlodipine besylate (calcium channel blocker)</i>		
<i>Sevikar HCT</i>		2010	<i>Sevikar HCT: A triple combination drug of olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate</i>		

ASCA Unit

Brand Name (Generic Name)	Efficacy	Launched	Remarks	Revenue (Billions of yen)	
				FY2021 results	YoY
				114.1	14.5
<i>Enhertu</i> (<i>trastuzumab deruxtecan</i>)	Anti-cancer agent (HER2 directed antibody drug conjugate)	2022	Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.	1.4	1.4
<i>Lixiana</i> (<i>edoxaban</i>)	Anticoagulant	2016	Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.	14.3	5.4

Daiichi Sankyo Healthcare Unit

Brand Name	Efficacy	Revenue (Billions of yen)	
		FY2021 results	YoY
		64.7	-2.5
<i>Lulu</i>	Combination cold remedy		
<i>Loxonin S</i>	Antipyretic analgesic / topical anti-inflammatory analgesic		
<i>Transino</i>	Melasma improvement / treatment against spots and freckles		
<i>Minon</i>	Skincare		
<i>Breath Labo</i>	Oral care		
<i>Clean Dental</i>	Oral care		



Lulu



Minon